Altered fibrin clot properties in patients with premature peripheral artery disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 12, 2012, Pages 608-615

  Okraska Bylica, Agnieszka ^a   Wilkosz, Tadeusz ^a   Słowik, Lidia ^b   Bazanek, Marta ^a   Konieczyńska, Małgorzata ^a   Undas, Anetta ^b  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Ankle brachial index; D dimer; Fibrin clot; Peripheral artery disease

Indexed keywords

C REACTIVE PROTEIN; D DIMER; GLUCOSE;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRIN CLOT; FIBRINOGEN BLOOD LEVEL; GERIATRIC PATIENT; HUMAN; LYSIS; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; RISK FACTOR;

EID: 84872337950     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1535     Document Type: Article

References (29)

1. Brevetti G, Giugliano G, Brevetti L, Hiatt WR. Inflammation in peripheral artery disease. Circulation. 2010; 122: 1862-1875.
2. Undas A. Acquired dysfibrinogenemia in atherosclerotic vascular disease. Pol Arch Med Wewn. 2011; 121: 310-319.
3. Batholomew JR, Olin JW. Pathophysiology of peripheral arterial disease and risk factors for its development. Cleve Clin J Med. 2006; 73: S8-S14.
4. Balagopal P, de Ferranti SD, Cook S, et al.; American Heart Association Committee on Atherosclerosis Hypertension and Obesity in Youth of the Council on Cardiovascular Disease in the Young; Council on Nutrition, Physical Activity and Metabolism; Council on Epidemiology and Prevention. Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical consideration for youth: a scientific statement from the American Heart Association. Circulation. 2011; 123: 2749-2769.
5. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the national Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004; 110: 738-743. (Pubitemid 39056275)
6. Wildman RP, Muntner P, Chen J, et al. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am J Cardiol. 2005; 96: 1579-1583. (Pubitemid 41690183)
7. Lane JS, Vittinghoff E, Lane KT, et al. Risk factors for premature peripheral vascular disease: results for the National Health and Nutritional Survey, 1999-2002. J Vasc Surg. 2006; 44: 319-324.
8. Unlü Y, Karapolat S, Karaca Y, Kiziltunç A. Comparison of levels of inflammatory markers and hemostatic factors in the patients with and without peripheral arterial disease. Thromb Res. 2006; 117: 357-364. (Pubitemid 43197485)
9. Mota AP, de Castro Santos ME, Lima e Silva FC, et al. Hypercoagulability markers in patients with peripheral arterial disease: association to ankle-brachial index. Angiology. 2009; 60: 529-535.
10. Tzoulaki I, Murray GD, Price JF, et al. Hemostatic factors, inflammatory markers, and progressive atherosclerosis: the Edinburgh Artery Study. Am J Epidemiol. 2006; 63: 334-341. (Pubitemid 43238427)
11. Vig S, Chitolie A, Sleight S, et al. Prevalence and risk of thrombophilia defects in vascular patients. Eur J Vasc Surg. 2004; 28: 124-131. (Pubitemid 38976447)
12. Cieśla-Dul M, Gawȩda B, Wypasek E, et al. Residual iliofemoral thrombosis in a 31-year-old woman on oral contraceptives possessing heterozygous factor V Leiden, factor XIII Val34Leu allele and alpha-fibrinogen Thr312Ala allele: case report. Pol Arch Med Wewn. 2009; 119: 822-825.
13. de Bruijne EL, Gils A, Rijken DC, et al. High thrombin activatable fibrin-olysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. Thromb Res. 2011; 127: 254-258.
14. Undas A, Ariëns RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011; 31: e88-e99.
15. Scott EM, Ariëns RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol. 2004; 24: 1558-1566. (Pubitemid 39180877)
16. Undas A, Szułdrzyński K, Stȩpień E, et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis. 2008; 196: 551-558.
17. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006; 26: 2567-2573. (Pubitemid 44607482)
18. Undas A, Podolec P, Zawilska K, et al. Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischemic stroke. Stroke. 2009; 40: 1499-1501.
19. Undas A, Zawilska K, Ciesla-Dul M, et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood. 2009; 114: 4272-4278.
20. Guimaráes AH, de Bruijne EL, Lisman T, et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol. 2009; 145: 115-120.
21. Undas A, Nowakowski T, Cieśla-Dul M, al Sadowski J. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangitis obliterans. Atherosclerosis. 2011; 215: 481-486.
22. Bhasin N, Ariens RA, West RM, et al. Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication. J Vasc Surg. 2008; 48: 1497-1503.
23. Criqui MH, McClelland RL, McDermott MM, et al. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010; 56: 1506-1512.
24. Carpenter JP, Lexa FJ, Davis JT. Determination of duplex Doppler ultrasound criteria appropriate to the North American Symptomatic Carotid Endarterectomy Trial. Stroke 1996; 27: 695-699. (Pubitemid 26114435)
25. Mills JD, Ariëns RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation. 2002; 106: 1938-1942. (Pubitemid 35176298)
26. Undas A, Topór-Madry R, Tracz W, Pasowicz M. Effect of cigarette smoking on plasma fibrin clot permeability and susceptibility to lysis. Thromb Haemost. 2009; 102: 1289-1291.
27. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012; 33: 1635-1701.
28. Szułdrzyński K, Zalewski J, Machnik A, Zmudka K. Elevated levels of 8-iso-prostaglandin F2alpha in acute coronary syndromes are associated with systemic and local platelet activation. Pol Arch Med Wewn. 2010; 120: 19-24.
29. Sliz D, Mamcarz A, Filipiak KJ, et al. 3ST-POL trial: standards of statin use in Poland in the context of the European Society of Cardiology guidelines. Pol Arch Med Wewn. 2010; 120: 328-333.